Core Insights - The company reported a revenue of 31.83 billion yuan for the year 2025, representing a year-on-year growth of 10.3% [1] - Adjusted net profit attributable to shareholders reached 4.54 billion yuan, with a year-on-year increase of 31.4%, marking four consecutive reporting periods of double-digit growth [1] Business Development Activities - In January 2026, the company acquired Hegia, a siRNA company, for 1.2 billion yuan, gaining access to its long-acting siRNA delivery platform [1] - In February 2026, a global collaboration was established with Sanofi for the JAK/ROCK inhibitor Rovasi, setting a record transaction amount in the transplantation field [1] - In July 2025, the company fully acquired Lixin Pharmaceutical for 950 million USD, obtaining its antibody discovery and ADC technology platform, along with several products in critical clinical stages [1] Pipeline Development - The company employs an "internal R&D + external mergers and acquisitions" strategy, with multiple globally promising products in its pipeline [2] - In the oncology sector, LM-302 (Claudin18.2 ADC) has completed enrollment for a Phase III trial in third-line gastric cancer, while a Phase III trial for first-line gastric cancer has been initiated [2] - LM-108 (CCR8 monoclonal antibody) has entered Phase III for second-line gastric cancer [2] - In liver disease and cardiovascular metabolism, Kylo-11 LPA siRNA is in Phase II clinical trials, with Kylo-12 (APOC3 siRNA) expected to start Phase II in the second half of 2026 [2] - The company has several products in the weight loss and muscle gain sector, with HJY-10 (INHBE siRNA) anticipated to enter clinical trials by 2026 [2] - Data from a Phase I trial of a PD-1/VEGF dual antibody, licensed to Merck, is planned to be presented at AACR in 2026 [2]

Investment Rating - The report initiates coverage with a "Buy" rating for the company [4]. Core Insights - The company focuses on innovative therapies for cancer and metabolic diseases, with a strong emphasis on addressing unmet medical needs in obesity and tumor treatment [1][11]. - LAE102, a globally pioneering ActRIIA monoclonal antibody, aims to mitigate muscle loss associated with GLP-1 receptor agonist weight loss therapies, showing promising results in early clinical trials [2][38]. - Afuresertib (LAE002), a broad-spectrum AKT kinase inhibitor, is currently in late-stage clinical trials for HR+/HER2- breast cancer, demonstrating significant potential as a new treatment option for resistant cases [3]. Summary by Sections Company Overview - Laekna Therapeutics, established in 2016 and listed on the Hong Kong Stock Exchange in June 2023, is a biotechnology company dedicated to developing innovative therapies for cancer, metabolic diseases, and liver fibrosis [1][11]. LAE102 Development - LAE102 targets the ActRIIA receptor to counteract muscle loss caused by GLP-1 receptor agonists, with preclinical studies confirming its efficacy in promoting muscle growth and reducing fat accumulation [2]. - The drug has shown excellent safety and tolerability in Phase I trials, with no serious adverse events reported [38]. Afuresertib (LAE002) Development - Afuresertib is an oral, reversible, ATP-competitive AKT inhibitor that effectively suppresses tumor cell growth and metastasis by inhibiting the PI3K/AKT/mTOR signaling pathway [3]. - The drug is currently in Phase III clinical trials for HR+/HER2- breast cancer, with promising results in earlier phases indicating its potential as a new treatment for resistant breast cancer [3]. Financial Projections - The company anticipates revenues of 44 million, 50 million, and 76 million yuan for the years 2025, 2026, and 2027, respectively, with projected net losses of 271 million, 298 million, and 254 million yuan for the same years [4].